Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,472
datasets available to search
ShareScore release 0.9.0
Dataset results
1,472 results for “EGFR”
Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations
ClinicalTrials.gov study NCT04687241. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Immunohistochemical Expression of EGFR in the Patients Having Oral Squamous Cell Carcinoma
ClinicalTrials.gov study NCT06606301. IPD Sharing: NO. Countries: 1. Publications: 3.
Study to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving Osimertinib (CULTRO)
ClinicalTrials.gov study NCT05998993. IPD Sharing: YES. Countries: 1. Publications: 30.
Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma
ClinicalTrials.gov study NCT05132985. IPD Sharing: NO. Countries: 1. Publications: 7.
Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI
ClinicalTrials.gov study NCT04007835. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis
ClinicalTrials.gov study NCT04944069. IPD Sharing: NO. Countries: 1. Publications: 19.
Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
ClinicalTrials.gov study NCT05681780. IPD Sharing: NO. Countries: 1. Publications: 1.
Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients
ClinicalTrials.gov study NCT03382795. IPD Sharing: Not stated. Countries: 1. Publications: 18.
Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in NSCLC Patients Activating EGFR Mutations
ClinicalTrials.gov study NCT02759614. IPD Sharing: YES. Countries: 1. Publications: 3.
Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma
ClinicalTrials.gov study NCT04201756. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Epidemiological Study to Evaluate the Prevalence of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (
ClinicalTrials.gov study NCT01081496. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Non-interventional, Prospective Study to Determine Prevalence of EGFR Mutations in Non-small Cell Lung Cancer
ClinicalTrials.gov study NCT04742192. IPD Sharing: YES. Countries: 15. Publications: 1.
Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)
ClinicalTrials.gov study NCT02206763. IPD Sharing: Not stated. Countries: 1. Publications: 1.
BPI-7711 Capsule in Patients With EGFR Mutation T790M Positive Non-small Cell Lung Cancer
ClinicalTrials.gov study NCT03386955. IPD Sharing: NO. Countries: 1. Publications: 3.
Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations
ClinicalTrials.gov study NCT04923906. IPD Sharing: NO. Countries: 1. Publications: 0.
Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients
ClinicalTrials.gov study NCT03137264. IPD Sharing: NO. Countries: 2. Publications: 11.
Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT02609776. IPD Sharing: Not stated. Countries: 10. Publications: 8.
The Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer
ClinicalTrials.gov study NCT05167851. IPD Sharing: NO. Countries: 1. Publications: 2.
Liquid Biopsy as a Tool to Evaluate Resistance to First and Third (AZD9291) (EGFR) (TKIs) in (EGFR) Mutant NSCLC
ClinicalTrials.gov study NCT02771314. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study
ClinicalTrials.gov study NCT04122833. IPD Sharing: NO. Countries: 1. Publications: 5.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.